Theseus Pharmaceuticals, which aimed to overcome the resistance that cancers develop to drugs, is laying off most of its staff and exploring options that could lead to deals that eke out some value ...
Warning: This post discusses theories that could be potential spoilers for Fantastic Beasts: The Crimes of Grindelwald.Plenty of Harry Potter characters have names that are connected to their ...
Theseus Pharmaceuticals has launched from under the wing of healthcare fund manager OrbiMed with a $100 million series B financing and data to show that the new biotech’s gastrointestinal tumor ...
It’s been a wild November for Theseus Pharmaceuticals. Just a couple of weeks ago, the biotech laid off almost three-quarters of its staff. Days later, the company received offers from two sets of ...
Add Yahoo as a preferred source to see more of our stories on Google. A 1920s illustration of an ancient Greek Bireme that has two decks of oars. A 1920s illustration of an ancient Greek Bireme that ...
CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer ...
CAMBRIDGE, Mass., Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of ...
-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- The tender offer and related withdrawal rights expired at 6:00 p.m. Eastern Time on February 13, 2024 (the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results